Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth

Launched by FOLLICUM AB · Jun 3, 2016

Keywords

ClinConnect Summary

SAD part:

A total of 3 weeks dosing, the two lowest concentrations in week 1, dose 3 at week 2 and finally dose 4 at week 3.

MD part:

In total 12 weeks of dosing where group A will be dosed twice weekly and group B three times weekly

Each injection will be administered into one of five of the six randomized areas (10 cm apart, left and right side) from the subject's defined investigational skin areas. One area will be completely untreated.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Healthy male, aged 18-45 years
• • Clinically visible terminal hair growth on thighs
• Exclusion Criteria:
• • Damaged skin in or around test sites
• • History of any acute (e.g. acute infections) or chronic illness or known skin cancer that might confound the results of the trial
• • History or clinical signs of keloids or hypertrophic scars
• • Immunological disorders such as alopecia areata, and systemic lupus erythematosus
• • Current or within 2 weeks prior to first dosing use of vasodilating drugs (e.g. Pentoxifyllin, nitroglycerine) or anticoagulating drugs (e.g. heparine, cumarines, new oral anticoagulants)
• • Current or within 3 months prior to first dosing use of anti-inflammatory medication, corticosteroids or immunosuppressive drugs taken for more than 2 consecutive weeks
• • Current or within 3 months prior to first dosing use of medication with hair growth modifying properties like minoxidil, diazoxid, cyclosporine, antiandrogens
• • Current or within 12 months prior to first dosing intake of anabolics or 5-alpha reductase inhibitors
• • Current or within one week prior to first dosing use of any topical drugs on the legs